Guangji Pharmaceutical Financial Risk Analysis And Control

Financial risk management is an important financial management activities of the branch, Its significance lies in the possibility of strengthening the enterprises to cope with the financial activities of economic losses due to subjective or objective factors caused. Pharmaceutical manufacturing industry known as "the sun never decline," said the industry, and with the accelerated aging of our population, a large health awareness raising and so will drive the development of the pharmaceutical manufacturing industry ushered in a wave, but a sunrise industry does not mean that no risk of development. With the deepening of China's market-oriented reforms of the economy, competition among enterprises has become increasingly fierce, the development of enterprises are facing more and more financial risk. The pharmaceutical manufacturing industry and capital-intensive, innovation-driven industries, financial risk-sensitive enterprises strengthened, thereby enhancing even more financial risk management is particularly necessary.This paper reviews the basis of relevant theories of financial risk management, including financial risk concept, causes and classification, and describes the basic flow of financial risk management. On this basis, in order to Guang Ji Pharmaceutical as a case study to expand its financing risk, investment risk, distribution of income and capital recovery risk risk identification, the pharmaceutical industry and selected 139 sample companies, using factor analysis to extract the index system Construction of financial risk evaluation system for the pharmaceutical industry, analysts pointed out that the risk of Guang ji pharmaceutical in solvency, profitability, operating capabilities, capacity development and cash flow exists. Finally, put forward corresponding control measures against financial risks Guang Ji Pharmaceutical identified the existence of.In this paper, the desired sample by the pharmaceutical industry companies to establish financial risk evaluation system applicable to the pharmaceutical industry, and for the financial risks identified herein can be effectively controlled. And to be able to provide a useful reference for other financial risk assessment of the pharmaceutical industry, the pharmaceutical industry to strengthen the company's financial risk management.